AC Immune SA Income Statement 2025-2011 | ACIU

Brief overview of profit and loss at AC Immune SA

The overview follows changes across a five-year period. Revenue reported by AC Immune SA was 15.4 million Swiss francs at the beginning of the period and 3.6 million Swiss francs at the end. Across the full period, sales moved by −76.8%; the average annual rate was −25.4%. The business finished the period with a smaller revenue base.

The five-year EBITDA result moved by −13.2%: from −61.3 million Swiss francs to −69.3 million Swiss francs. Operating profitability strengthened faster than the scale of sales. At the operating-margin level, the figure shifted from −397% to −1940.1%. Operating return per unit of revenue declined.

Net income moved from −61.9 million Swiss francs at the start to −70.4 million Swiss francs at the end. The loss widened and increased the financial risk.

The five-year change in capitalization reached −46.8%: from 540 million Swiss francs to 287 million Swiss francs. The negative valuation trend points to increased investor caution.

Financial takeaway

The financial trajectory is weak and requires a cautious interpretation. The most visible risks are a weaker market valuation, limited revenue growth and a narrow EBITDA buffer. The key question is whether sales can be converted into sustainable profit.